The reinforcing effects of nicotine and stimulant medication in the everyday lives of adult smokers with ADHD: A preliminary examination.
Whereas the smoking prevalence rates in the general population are declining, rates among people diagnosed with attention-deficit/hyperactivity disorder (ADHD) continue to be elevated. Previous research has shown that nicotine may improve attention and mood, suggesting that nicotine may help ameliorate the attentional and emotional problems associated with ADHD. The present study examined the effects of nicotine with and without stimulant medication on ADHD symptoms, moods, and arousal in the everyday lives of smokers with ADHD. A total of 10 smokers with ADHD who were being treated with stimulant medication were asked to abstain from smoking while participating in the study. Participants underwent four conditions in randomized order: (a) Nicotine patch+stimulant medication, (b) nicotine patch only, (c) placebo patch+stimulant medication, and (d) placebo patch only. Each condition continued for 2 days, during which self-reports of ADHD symptoms and moods were obtained using electronic diaries. Lightweight ambulatory monitors recorded cardiovascular activity at each diary entry. Smoking abstinence was verified by expired carbon monoxide and salivary cotinine analysis. Results showed that nicotine patches and stimulant medication alone and in combination reduced difficulty concentrating and core ADHD symptoms compared with placebo patch only. Borderline improvement in impatience and self-control was seen with nicotine patch administration primarily on day 1. Nicotine patches also tended to elevate systolic and diastolic blood pressure compared with placebo patch during day 2. The findings suggest that smokers with ADHD experience nicotine-related reductions in ADHD symptoms during their everyday lives.
Department of Psychiatry and Human Behavior, D402 Medical Sciences I, Irvine, CA 92697-1675, USA. jgehricke@uci.edu
Jean-G
JG
Gehricke
Carol K
CK
Whalen
Larry D
LD
Jamner
Tim L
TL
Wigal
Kenneth
K
Steinhoff
D000279:Administration, Cutaneous; D000328:Adult; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy* / Q000453:epidemiology*; D002248:Carbon Monoxide / Q000032:analysis; D000697:Central Nervous System Stimulants / Q000627:therapeutic use*; D003367:Cotinine / Q000032:analysis; D003710:Demography; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008774:Methylphenidate / Q000627:therapeutic use*; D009538:Nicotine / Q000008:administration & dosage / Q000627:therapeutic use*; D015995:Prevalence; D012054:Reinforcement, Psychology; D012463:Saliva / Q000737:chemistry; D012907:Smoking / Q000453:epidemiology
D000697:Central Nervous System Stimulants; D008774:Methylphenidate; D009538:Nicotine; D002248:Carbon Monoxide; D003367:Cotinine